Response to Chand et al

doi:doi:10.1038/sj.leu.2403314

Leukemia (2004) 18, 887. doi:10.1038/sj.leu.2403314 Published online 12 February 2004

Response to Chand et al

C Gambacorti-Passerini^1,2

¹National Cancer Institute, Milano, Italy
²Department of Oncology, Mc Gill University, JGH, Montreal, Canada

Correspondence: C Gambacorti-Passerini, National Cancer Institute, Milano, Italy. E-mail: carlo.gambacorti@istitutotumori.mi.it

Received 18 November 2003; Accepted 9 December 2003; Published online 12 February 2004.

TO THE EDITOR

The report from Chand et al. offers clinical confirmation to our initial findings, although the data are, as for any unplanned clinical observation on a single patient, far from definitive and require further verification.

In certain conditions of particular demand, such as the repopulation after cytotoxic treatment as described in our paper,¹ the stimulation with growth factors,² or the clinical situation presented by Chand, it is likely that the known inhibitory effect of imatinib on c-Kit, can cause clinically evident alterations.

Top

References

Ruchatz H, Puttini M, Cleris L, Pilotti S, Gambacorti-Passerini C, Formelli F. Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia 2003; 17: 298–304. | Article | PubMed |
Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour JF et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003; 17: 821–828. | Article | PubMed | ISI | ChemPort |